Ociperlimab

DRUG15 trials

Sponsors

Beigene Ltd., BeOne Medicines AG, BeiGene, BeOne Medicines, Novartis Pharmaceuticals

Conditions

Advanced Hepatocellular CarcinomaAdvanced MalignanciesCervical CancerEsophageal Squamous Cell CarcinomaLimited Stage Small Cell Lung CancerLocally Advanced and Metastatic Solid TumorsLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)Locally advanced

Phase 1

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

CompletedNCT04047862

BeiGeneLocally Advanced and Metastatic Solid Tumors

Start: 2019-08-15End: 2024-08-07Updated: 2025-08-22

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

CompletedNCT05267054

BeiGeneRefractory Diffuse Large B-cell Lymphoma, Relapsed Diffuse Large B-cell Lymphoma

Start: 2022-04-25End: 2024-08-30Updated: 2025-09-15

Phase 2

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

CompletedNCT04693234

BeiGeneCervical Cancer

Start: 2021-02-15End: 2023-08-31Updated: 2025-04-27

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

CompletedNCT04732494

BeiGeneEsophageal Squamous Cell Carcinoma

Start: 2021-03-31End: 2023-12-26Updated: 2025-01-31

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

CompletedNCT04948697

BeiGeneAdvanced Hepatocellular Carcinoma

Start: 2021-08-20End: 2024-02-01Updated: 2025-02-24

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

CompletedNCT04952597

BeiGeneLimited Stage Small Cell Lung Cancer

Start: 2021-07-15End: 2023-07-26Updated: 2024-10-26

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

CompletedNCT05014815

BeiGeneLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV

Start: 2021-11-16End: 2024-09-04Updated: 2025-09-16

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

CompletedNCT05577702

BeiGeneNon Small Cell Lung Cancer

Start: 2023-03-08End: 2025-01-23Updated: 2026-02-09

Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer

WithdrawnNCT05809895

Novartis PharmaceuticalsTriple Negative Breast Cancer

Start: 2023-09-15End: 2029-07-18Updated: 2023-07-24

Phase 3

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Active, not recruitingNCT04164199

BeOne MedicinesAdvanced Malignancies

Start: 2019-12-19End: 2026-07-01Updated: 2026-03-27

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Active, not recruitingNCT04746924

BeiGeneNon-small Cell Lung Cancer, NSCLC

Start: 2021-06-08End: 2026-03-31Updated: 2025-06-24

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

TerminatedNCT04866017

BeiGeneNon Small Cell Lung Cancer

Start: 2021-06-17End: 2023-10-17Updated: 2024-10-31

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.

WithdrawnNCT05791097

Novartis PharmaceuticalsNon-small Cell Lung Cancer (NSCLC)

Start: 2023-07-28End: 2027-12-26Updated: 2023-07-24

A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

CompletedCTIS2023-507317-10-00

Beigene Ltd.Locally advanced, or metastatic non small cell lung cancer, unresectable

Start: 2021-05-10End: 2025-03-25Target: 135Updated: 2025-04-10

An Open-Label, Multicenter, Long-term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies

RecruitingCTIS2023-508883-31-00

BeOne Medicines AGSolid tumors and hamatological malignancies

Start: 2021-02-23Target: 21Updated: 2026-01-20

Related Papers

AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC.

2025-09-26

AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer.

2025-05-23

Abstract 4558: Comparative analysis of blood- and tissue-informed MRD studies in SCLC

Cancer Research2025-04-21

Abstract CT255: AdvanTIG-204: A phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC)

Cancer Research2024-04-058 citations

Abstract CT053: Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC)

Cancer Research2024-04-05

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2023-10-0139 citations

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations

AdvanTIG-105: Phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC).

JCO Global Oncology2023-08-011 citations

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.

2023-07-2010 citations

AdvanTIG-105: A phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC).

Journal of Clinical Oncology2023-06-013 citations

148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)

Immuno-Oncology Technology2022-12-013 citations

126P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer (NSCLC)

Immuno-Oncology Technology2022-12-012 citations

768 Peripheral pharmacodynamic (PD) effects of ociperlimab (OCI) in combination with tislelizumab (TIS) in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study

Regular and Young Investigator Award Abstracts2022-11-012 citations

AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2022-06-013 citations

AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).

Journal of Clinical Oncology2022-01-193 citations

AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2022-01-191 citations

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

Clinical Cancer Research2021-10-2944 citations

AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2021-05-2017 citations

AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2021-05-208 citations

AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.

Journal of Clinical Oncology2021-05-207 citations

1 more papers not shown